Want to see FR:ALSEN full AI Analyst Report?
Top Page
Sensorion SAS
(ALSEN)
Select Model
Select Model
Rating:45Neutral
Price Target:
€9.00
▲(3233.33% Upside)
Action:Reiterated
Date:10/21/26
The score is held down primarily by weak financial performance: persistent large losses, heavy ongoing cash burn, and the sharp 2025 revenue drop to zero increase reliance on external funding. Technicals add further pressure with the price below key longer-term moving averages and a negative MACD. Valuation provides limited support because the negative P/E reflects continued unprofitability and no dividend yield is available.
Positive Factors
Low Leverage
Low leverage and modest debt provide more financial flexibility than a highly indebted biotech, helping preserve options to fund research and absorb setbacks. This is a durable balance-sheet advantage, although it does not remove the need to finance ongoing losses.
Negative Factors
Revenue Disruption
The fall to zero revenue represents a major break from the prior growth trajectory and increases uncertainty around the company’s ability to generate operating income. Without an established recurring revenue stream, funding future clinical development remains dependent on external sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Low leverage and modest debt provide more financial flexibility than a highly indebted biotech, helping preserve options to fund research and absorb setbacks. This is a durable balance-sheet advantage, although it does not remove the need to finance ongoing losses.
Read all positive factors
Sensorion SAS (ALSEN) vs. iShares MSCI France ETF (EWQ)
Market Cap
€94.08M
Dividend YieldN/A
Average Volume (3M)23.89K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth6.26%
CountryFR
Employees66
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.24
Shares Outstanding10,312,972
10 Day Avg. Volume25,736
30 Day Avg. Volume23,885
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€41.00Price Target Upside15085.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.44
Revenue Forecast (FY)€4.46M
Sensorion SAS Business Overview & Revenue Model
Company Description
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing f...
How the Company Makes Money
Sensorion primarily makes money through (1) collaboration and licensing arrangements and (2) external funding mechanisms typical of R&D-stage biopharma, rather than recurring product sales.
1) Collaboration and licensing revenue: The company can ...
Sensorion SAS Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 6.65M | 5.70M | 4.93M | 4.26M |
| Gross Profit | -1.58M | -1.36M | 6.65M | 3.79M | 4.16M | 3.75M |
| EBITDA | -42.27M | -36.31M | -28.22M | -20.64M | -22.44M | -17.46M |
| Net Income | -34.13M | -29.43M | -25.97M | -22.06M | -23.21M | -15.14M |
Balance Sheet | ||||||
| Total Assets | 100.77M | 57.89M | 89.28M | 46.50M | 38.93M | 59.02M |
| Cash, Cash Equivalents and Short-Term Investments | 88.49M | 47.46M | 76.98M | 36.97M | 26.20M | 50.00M |
| Total Debt | 3.20M | 1.28M | 2.20M | 2.87M | 3.76M | 3.99M |
| Total Liabilities | 19.20M | 13.41M | 17.14M | 13.23M | 17.06M | 15.03M |
| Stockholders Equity | 81.56M | 44.48M | 72.14M | 33.27M | 21.87M | 43.98M |
Cash Flow | ||||||
| Free Cash Flow | -26.54M | -27.64M | -22.45M | -21.94M | -22.92M | -11.81M |
| Operating Cash Flow | -26.21M | -27.39M | -21.33M | -21.07M | -21.41M | -10.77M |
| Investing Cash Flow | -35.68M | 9.24M | -11.13M | -381.06K | -1.54M | -1.07M |
| Financing Cash Flow | 58.36M | -1.16M | 62.26M | 32.20M | -820.68K | -715.07K |
Sensorion SAS Technical Analysis
Neutral
0.27
Price Trends
10.00
Negative
11.78
Negative
15.63
Negative
Market Momentum
-0.39
Negative
59.03
Neutral
78.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Neutral. The current price of 0.27 is below the 20-day moving average (MA) of 6.98, below the 50-day MA of 10.00, and below the 200-day MA of 15.63, indicating a neutral trend. The MACD of -0.39 indicates Negative momentum. The RSI at 59.03 is Neutral, neither overbought nor oversold. The STOCH value of 78.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALSEN.
Sensorion SAS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €977.76M | -28.44 | ― | ― | -23.21% | -50.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €189.79M | -4.06 | -29.36% | ― | 189.81% | 38.50% | |
46 Neutral | €18.04M | -1.01 | 52.39% | ― | -610.31% | 43.88% | |
45 Neutral | €94.08M | -2.17 | -54.15% | ― | ― | 6.26% | |
41 Neutral | €71.96M | -1.71 | -94.14% | ― | -5.98% | -8.67% |
* Healthcare Sector Average
FR:ALSEN
Sensorion SAS
9.03
-9.17
-50.41%
FR:ALCOX
Nicox SA
0.29
-0.07
-18.89%
FR:TNG
Transgene
0.68
-0.66
-49.44%
FR:SIGHT
GenSight Biologics SA
0.07
-0.05
-38.14%
FR:ALCLS
Cellectis SA
0.95
-2.03
-68.26%
FR:MEDCL
MedinCell SA
26.22
-8.66
-24.83%
Sensorion SAS Corporate Events
Sensorion hires veteran gene therapy leader Peter Weber as Chief Medical Officer
Oct 19, 2026
Sensorion has appointed Peter Weber, MD, MBA, an otologist and neurotologist with more than two decades of clinical and industry leadership in hearing loss, as Chief Medical Officer effective November 2, 2026. He previously led development of the ...
Sensorion names new CFO as flagship hearing gene therapy nears clinic
Oct 7, 2026
Sensorion has appointed seasoned biopharmaceutical executive Louis J. Arcudi III as Chief Financial Officer, effective October 7, 2026, succeeding Laurene Danon, who will stay on as adviser to ensure a smooth handover. Arcudi, based in the Boston ...
Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II
Sep 23, 2026
Sensorion has sharpened its strategic focus on SENS-601, a single-vector AAV gene therapy for GJB2-related hearing loss, securing Clinical Trial Application filings in France and Canada and Fast Track assessment in France, and winning authorizatio...
Sensorion to Spotlight Lead Gene Therapy SENS-601 in Dedicated Program Day
Sep 18, 2026
Sensorion will host a dedicated SENS-601 Program Day on September 22, 2026, to showcase its lead gene therapy targeting GJB2-related hearing loss and the design of its HearConnex clinical trial. The virtual event, featuring company executives and ...
Sensorion Eyes U.S. IPO to Bolster Hearing-Loss Therapy Pipeline
Sep 16, 2026
Sensorion SAS has confidentially submitted a draft registration statement to the U.S. Securities and Exchange Commission as it evaluates a potential initial public offering of ordinary shares, possibly in the form of American Depositary Shares lis...
Sensorion Wins Fast-Track French Approval for First SENS-601 Gene Therapy Trial
Sep 3, 2026
Sensorion has secured authorization from France’s ANSM, via a Fast Track procedure, to launch HearConnex, a Phase I/II trial of its lead gene therapy SENS-601 for GJB2 gene-related congenital deafness, with the first patient dosing targeted ...
Sensorion Launches Technical Reverse Stock Split on Euronext Growth
Jul 29, 2026
Sensorion has announced a technical reverse stock split of its shares on Euronext Growth Paris, consolidating 50 existing shares with a nominal value of €0.10 into 1 new share with a nominal value of €5, without altering the total shar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.